Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Clinical trial NCT04940052 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04940052
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-15
- Primary completion
- 2025-01-22
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.